Literature DB >> 27878751

Assessment of the relationship between serum paraoxonase activity and epicardial adipose tissue in hemodialysis patients.

Emad Abdallah1, Samya El-Shishtawy2, Nevine Sherif2, Ahmed Ali3, Omnia El-Bendary4.   

Abstract

PURPOSE: Paraoxonase-1 (PON-1) is a high-density lipoprotein-associated (HDL) enzyme, which has been shown to reduce susceptibility to low-density lipoprotein (LDL) peroxidation. Epicardial adipose tissue (EAT) is a marker of atherosclerosis. The aim of this study was to determine the relationship between PON-1 activity and EAT in hemodialysis (HD) patients.
METHODS: This is a cross-sectional study conducted on 72 (43 males) HD patients with end-stage renal disease. Serum levels for lipid profiles, C-reactive protein, calcium, phosphate, and parathyroid hormone were measured. PON-1 activity was also measured and compared to the rate of enzymatic hydrolysis of paraoxon to p-nitrophenol. Echocardiography was used to measure EAT thickness (EATT). The correlation between PON-1 and EATT was assessed, while independent predictors of EATT in HD patients were similarly assessed using multivariate regression analysis.
RESULTS: There was a significant low mean value of PON-1 activity in HD patients compared with the control group (82.1 ± 31.6 vs. 164.3 ± 61.5 U/l, p = 0.0001) and significant high mean value of EATT in HD patients, compared with controls (6.2 ± 1.7 vs. 3.9 ± 1.1 mm, p = 0.0001). In addition, there was a significant negative correlation between PON-1 activity and EATT (r = -0.484, p = 0.0001) and a significant positive correlation between PON-1 activity and HDL-C (r = 0.417, p = 0.0003). PON-1, total cholesterol, triglycerides, LDL, HDL, age, and body mass index were found to be independent predictors of EATT.
CONCLUSION: Our study demonstrated that PON-1 activity was significantly lower in HD patients compared with healthy controls and that PON-1 activity was inversely correlated with EATT in this population.

Entities:  

Keywords:  Epicardial adipose tissue; Hemodialysis; Paraoxonase-1 activity

Mesh:

Substances:

Year:  2016        PMID: 27878751     DOI: 10.1007/s11255-016-1465-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  33 in total

1.  RP-HPLC determination of paraoxonase 3 activity in human blood serum.

Authors:  Zofia Suchocka; Joanna Swatowska; Jan Pachecka; Piotr Suchocki
Journal:  J Pharm Biomed Anal       Date:  2006-04-18       Impact factor: 3.935

2.  Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome.

Authors:  R Scott Rector; Shana O Warner; Ying Liu; Pamela S Hinton; Grace Y Sun; Richard H Cox; Craig S Stump; M Harold Laughlin; Kevin C Dellsperger; Tom R Thomas
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-05-01       Impact factor: 4.310

Review 3.  The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis.

Authors:  Simon W Rabkin
Journal:  Metab Syndr Relat Disord       Date:  2013-11-12       Impact factor: 1.894

4.  Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure.

Authors:  O Hasselwander; D McMaster; D G Fogarty; A P Maxwell; D P Nicholls; I S Young
Journal:  Clin Chem       Date:  1998-01       Impact factor: 8.327

5.  Epicardial adipose tissue volume and cardiovascular disease in hemodialysis patients.

Authors:  Mehmet Nuri Turan; Ozkan Gungor; Gulay Asci; Fatih Kircelli; Turker Acar; Mustafa Yaprak; Naim Ceylan; Meltem Sezis Demirci; Selen Bayraktaroglu; Huseyin Toz; Mehmet Ozkahya; Ercan Ok
Journal:  Atherosclerosis       Date:  2012-11-06       Impact factor: 5.162

6.  Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).

Authors:  Madeleine V Pahl; Zhenmin Ni; Lili Sepassi; Hamid Moradi; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2009-03-18       Impact factor: 5.992

7.  Decrease of serum paraoxonase activity in chronic renal failure.

Authors:  T F Dantoine; J Debord; J P Charmes; L Merle; P Marquet; G Lachatre; C Leroux-Robert
Journal:  J Am Soc Nephrol       Date:  1998-11       Impact factor: 10.121

8.  Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.

Authors:  Hamid Moradi; Madeleine V Pahl; Reza Elahimehr; Nosratola D Vaziri
Journal:  Transl Res       Date:  2008-12-10       Impact factor: 7.012

9.  Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia.

Authors:  Jerzy Bełtowski; Grazyna Wójcicka; Anna Jamroz
Journal:  Atherosclerosis       Date:  2003-09       Impact factor: 5.162

Review 10.  Epicardial fat: definition, measurements and systematic review of main outcomes.

Authors:  Angela Gallina Bertaso; Daniela Bertol; Bruce Bartholow Duncan; Murilo Foppa
Journal:  Arq Bras Cardiol       Date:  2013-07       Impact factor: 2.000

View more
  3 in total

1.  Relationship Between Epicardial Adipose Tissue and Body Composition as Determined by Multi-Frequency Bioelectrical Impedance Analysis in Patients with Stage 5 Chronic Kidney Disease.

Authors:  Zülfükar Yilmaz; Hasan İnce; Emre Aydin; Yasar Yildirim; Fatma Yilmaz Aydin; Enver Yüksel; Aziz Karabulut; Lezgin Dursun; Ali Kemal Kadiroğlu; Mehmet Emin Yilmaz
Journal:  Med Sci Monit       Date:  2020-02-07

2.  Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients.

Authors:  Alicja E Grzegorzewska; Paulina Adamska; Ewa Iwańczyk-Skalska; Kamila Ostromecka; Leszek Niepolski; Wojciech Marcinkowski; Adrianna Mostowska; Wojciech Warchoł; Czesław Żaba; Paweł P Jagodziński
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

Review 3.  The Relationship of Epicardial Adipose Tissue and Cardiovascular Disease in Chronic Kidney Disease and Hemodialysis Patients.

Authors:  Kultigin Turkmen; Hakan Ozer; Mariusz Kusztal
Journal:  J Clin Med       Date:  2022-02-27       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.